Taysha (TSHA) Director Phillip Donenberg Receives RSU Award

What Happened Phillip B. Donenberg, a director of Taysha Gene Therapies (TSHA), received equity awards reported on a Form 4 dated 2026-06-02 for transactions on 2026-06-01. The filing shows an award of 21,335 restricted stock units (RSUs) and an additional 42,671 derivative RSUs, for a combined total of 64,006 units. Each line is reported at $0.00 per share (awards/grants), so no cash changed hands—these are compensation awards rather than purchases or sales.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-02 (timely filing).
• Items reported: 21,335 RSUs (line A) and 42,671 derivative RSUs (line A); total 64,006 units; reported price $0.00; total reported value $0.
• Vesting: Footnotes state the RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to Donenberg’s continued service as a director.
• Shares owned after transaction: not specified in the provided excerpt.
• No 10b5-1 plan, tax-withholding, or sale/exercise details noted in the provided data.

Context These entries are grant/award transactions (compensation) and do not represent open-market buying or selling. RSUs typically convert to shares upon vesting and are a form of long-term compensation for directors; they don’t imply an immediate buy or sell signal.